Last reviewed · How we verify
Vaginal swab
At a glance
| Generic name | Vaginal swab |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effects of Microbiological and Immunological Factors on the Lower Urinary Tract
- Testing RG1-VLP Vaccine to Prevent HPV-related Cancers (PHASE1)
- MATCHING - feMAle geniTal sCHistosomiasis IN miGrants Female Genital Schistosomiasis in Migrants Presenting to an Outpatient Clinic in Italy: Prevalence and Clinical Impact (NA)
- Comparison Between Liquid-Based Cytology And Molecular Screening For Detecting Precursor Lesions and Cervical Cancer (NA)
- Reproductive Axis Maturation in the Early Post-Menarchal Years
- Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
- Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population (NA)
- Concordance and Acceptability of Self-screening Compared to Screening Carried Out by a Health Professional for HPV, a Risk Factor for Anal Cancer, by Swab in People Living With HIV. A Randomized Controlled Crossover Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaginal swab CI brief — competitive landscape report
- Vaginal swab updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI